Big news for healthcare professionals! The European Medicines Agency has just approved the world’s first oral antiviral treatment specifically targeting Respiratory Syncytial Virus (RSV) in adults. This milestone comes amidst a surge in RSV cases among older populations across Europe. The new therapy is poised to reduce hospitalizations and improve patient outcomes, marking a transformative step in respiratory care. Are you ready to see how this innovation will impact your clinical practice?